Nyxoah Announces Preliminary Results for the Second Quarter of 2026

Nyxoah reported preliminary Q2 2026 global net revenue of ~€7.7m (+21% sequentially) and U.S. net revenue of ~€5.2m (+22% sequentially), citing momentum with 180 active high-volume accounts. The company also noted CMS has proposed reimbursement increases for the Genio procedure from $31,526 to $35,414 (+$3,888, +12%) and for ASC reimbursement from $27,563 to $31,722 (+$4,159, +15%), while securing $110m in aggregate financing in Q2. Full-year 2026 global net revenue guidance remains €36m–€40m, and cash/assets are estimated at ~€97.8m as of June 30, 2026.

Analysis

The cleanest read is that the market is getting two separate de-risking events at once: funding removes dilution/runway anxiety, while the reimbursement proposal improves the economics of each implant. That combination matters more for NYXH than the headline revenue rate, because early-stage medtech is usually valued on survivability and adoption inflection, not on current sales multiples. The next leg of upside is likely driven by whether activations convert into repeatable implants, not by additional surgeon training alone.

Second-order, the reimbursement change is not purely company-specific. It should lift the entire hypoglossal nerve stimulation category, including INSP, because payor math gets easier for hospitals and ASCs across the procedure class. NYXH’s relative opportunity is to outperform if its leadless/battery-free positioning makes it the incremental winner in CCC-eligible or device-sensitive patients, but the base case is category expansion rather than immediate share gain.

The contrarian risk is that investors overweight sequential revenue growth from a very small base and underweight conversion friction. The key falsifier over the next 1-3 months is whether the 427 prior-auth cases translate into a materially higher Q3 implant cadence; if not, the stock can give back quickly once the analyst-day enthusiasm fades. Over 6-18 months, the real determinant is whether CMS finalizes the proposed rates and whether NYXH can show gross margin and opex leverage before another financing window opens.

Key Decisions for Investors

• Trade idea: tactical long NYXH into the July 8 analyst day, sized small, with a 1-3 month catalyst window; thesis is that funding + reimbursement de-risking supports a multiple re-rate if management shows implant conversion data. Falsify if analyst day lacks conversion metrics or Q3 guidance implies growth is still account-addition driven rather than procedure-driven.
• Relative-value pair: long NYXH / short INSP over the next 1-3 months if you want to express category expansion with higher beta to reimbursement upside. Rationale: NYXH has more operating leverage to positive sentiment, while INSP is the cleaner incumbent and likely absorbs less incremental multiple expansion.
• Watchlist only: do not chase on the CMS proposal alone until the final rule is published; the proposed 12-15% uplift can be revised. Use the final OPPS/ASC rule in the fall as the key trigger for adding exposure.
• If holding NYXH, hedge event risk with short-dated calls against the analyst-day pop or trim into strength above any post-announcement gap unless Q3 conversion metrics improve. The stock is likely to trade on credibility of conversion, not on another quarter of training/account additions.
• Set an alert around Q3 revenue acceleration and cash burn. If revenue growth decelerates while cash burn remains elevated, the equity can reprice sharply lower despite the new financing because the market will start anticipating another raise within 6-12 months.